Where does Xenon Pharmaceuticals Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Xenon Pharmaceuticals Inc. ranks #6,609 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Xenon Pharmaceuticals Inc. hold?

Xenon Pharmaceuticals Inc. holds 51 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Xenon Pharmaceuticals Inc.'s Innovation Score?

Xenon Pharmaceuticals Inc. has an Innovation Score of 41.0 out of 100 (top 34% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Xenon Pharmaceuticals Inc. focus on?

Xenon Pharmaceuticals Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 45 patents, ranking #401 of 6,058 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Xenon Pharmaceuticals Inc.'s patent grant rate increasing or decreasing?

Xenon Pharmaceuticals Inc.'s recent grant velocity is -21% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Xenon Pharmaceuticals Inc.'s patents?

Xenon Pharmaceuticals Inc.'s patents average 21.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Xenon Pharmaceuticals Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Xenon Pharmaceuticals Inc.

USPTO PatentsView assignee record - 51 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Xenon ranks #6,609 of 49,997 tracked US assignees by granted-patent volume, with 51 patents across 11 technology areas.

#6,609
of 49,997 US assignees by volume: Top 34%
by Innovation Score (41.0/100): 21.9
avg claims per patent: -21%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6609 · Foreign Corporation #6,609 · 51 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 51 grants
UPPER-Q #6,609/49,997
PHOTO-FINISH Vestel Elektronik…
CPC-FOCUS A61P · 11 areas
INNOV-PAR 41.0/100
CLAIMS-DENSE 21.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -21% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Vestel Elektronik Sanayi ve Ticaret A. S. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Xenon’s 41.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.6 pts (33%) Velocity 2.5 pts (6%) Breadth 11.7 pts (29%) Claim depth 13.1 pts (32%)

Qualcomm Incorporated · highest

85
National Dentex · near

41
Reckitt Benckiser · near

41
Shanghai Ninth… · near

41
Tesseract Ventures · near

41
Xenon Pharmaceuticals · this assignee

41
3D Lighting… · lowest

7

What this shows Xenon's Innovation Score is 41.0/100 (top 34% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Xenon?

Each dot is one of Xenon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Xenon’s own 21.9 claims/patent is ABOVE the 12.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Xenon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Xenon's grants concentrate

Xenon Pharmaceuticals Inc. is a focused PatentsView assignee: 11 CPC subclasses with 88.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (9 grants) versus a trough of 1 in 2023. By volume, Xenon sits between Vestel Elektronik Sanayi ve Ticaret A. S. and Albireo AB.

Xenon's three-year grant acceleration

Xenon Pharmaceuticals Inc. shows 7 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Vestel Elektronik…

51
Viiv Healthcare U…

51
Waldemar Link & KG

51
Wapp Tech

51
Yoshino Gypsum

51
Xenon Pharmaceuti… ◀

51
AIC Innovations G…

50
Aker Solutions AS

50
Albireo AB

50

What this shows Xenon holds 51 patents at rank #6,609, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Xenon

By rank, the assignees closest to #6,609 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Xenon's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Xenon, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Xenon ranks #401 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (41 here).

Reckitt Benckiser LLC 41 National Dentex, LLC 41 Tesseract Ventures, LLC 41 Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine 41

Similar claim depth

Nearest assignees by average claims per patent (21.9 here).

VigNet Incorporated 21.9 avg Breathe Technologies, Inc. 21.9 avg UNIVERSITÄT ZÜRICH 21.9 avg TP Lab, Inc. 21.9 avg

Xenon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Xenon Pharmaceuticals Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	7.8%
2016	9	17.6%
2017	6	11.8%
2018	5	9.8%
2019	4	7.8%
2020	7	13.7%
2021	8	15.7%
2022	2	3.9%
2023	1	2.0%
2024	4	7.8%
2025partial year	1	2.0%

Which technologies does Xenon Pharmaceuticals Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 45

C07D - Heterocyclic Compounds 43

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 19

C07C - Acyclic OR Carbocyclic Compounds 12

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 9

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Xenon Pharmaceuticals Inc.'s patent record in context - here's where to go next.

Xenon Pharmaceuticals Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #6,609 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Xenon Pharmaceuticals Inc. against Vestel Elektronik Sanayi ve Ticaret A. S., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.